SARS-CoV-2 pneumonia

[키워드] absolute difference active cancer Admission age allergy ambient approved arterial blood Barcelona baseline biochemical Blinding Block randomisation block size Blood Breastfeeding C-reactive protein C-reactive protein (CRP candidate clinical Clinical outcome clinical outcomes clinical trial contraindication Control control group Controlled trial COVID-19 COVID-19 admission COVID-19 pneumonia criteria death decrease defined detect Deterioration Device diabete Diabetes Mellitus diagnosis of SARS-CoV-2 discretion dissemination drug drug treatment early treatment Effectiveness element elevated eligible emergency room ethics committee EudraCT exclusion criteria expected explained ferritin Follow-up followed by following glucocorticoid Glucocorticoids groups hospital Hospital admission hypertension ICU Identifier IL-6 immunosuppressants IMPROVE inclusion criteria independent Infection inflammatory biomarkers Informed consent intensive care intensive care unit interleukin interleukin-6 Intervention intervention group intravenous intravenous infusion Laboratory Loading dose Lopinavir Lopinavir/ritonavir maintenance dose management manic manic disorder mechanical ventilation Medical devices Medicine Medicines Methylprednisolone Nasopharyngeal swab nasopharyngeal swabs number objective outcome outcome assessor outcome assessors Outpatient oxygen oxygen saturation PaO parallel-group partial pressure Partial pressure of oxygen participant Patient patient age patients patients with COVID-19 Pharmacy Placebo Pneumonia polymerase chain Potential Pregnancy primary endpoint Primary outcome procalcitonin proportion protocol Psychiatric Psychological psychotic pulse Pulses Quadruple blind radiological random randomisation randomised randomised controlled trial randomizeR receive recommendation recruit recruitment Registered Remdesivir required researcher reverse transcriptase Reverse transcriptase polymerase chain reaction Ritonavir RT-PCR Sample size SARS-CoV-2 SARS-CoV-2 pneumonia sequence Spain Spanish sputum Standard of care status stratified study outcomes Study protocol supplementary material Symptom Tablet the patient therapy title total sample size transcriptase Treatment treatment failure Trial Trial registration two group two groups two-tailed type I type II error uncontrolled hypertension unit university Version website with COVID-19
[DOI] 10.1186/s13063-020-04999-4 PMC 바로가기 [Article Type] Letter